Primary Site >> Biliary tract Cancer

Gene >> AES

Journal: J Gastrointest Surg. 2008 Jan;12(1):129-37.
Title: Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
Author: Gusani, Niraj J|Balaa, Fady K|Steel, Jennifer L|Geller, David A|Marsh, J Wallis|Zajko, Albert B|Carr, Brian I|Gamblin, T Clark
PMID: 17851723
Journal: Cardiovasc Intervent Radiol. 2009 Nov;32(6):1187-92.
Title: OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma.
Author: Poggi, Guido|Amatu, A|Montagna, B|Quaretti, P|Minoia, C|Sottani, C|Villani, L|Tagliaferri, B|Sottotetti, F|Rossi, O|Pozzi, E|Zappoli, F|Riccardi, A|Bernardo, G
PMID: 19727937
Journal: Hepatogastroenterology. 2012 May;59(115):691-5.
Title: An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Author: Katayose, Yu|Ohtsuka, Hideo|Kitamura, Yo|Masuda, Kunihiro|Nakagawa, Kei|Yamamoto, Kuniharu|Yoshida, Hiroshi|Onogawa, Tohru|Motoi, Fuyuhiko|Naitoh, Takeshi|Rikiyama, Toshiki|Egawa, Shin-Ichi|Unno, Michiaki
PMID: 22469710
Journal: Ann Oncol. 2015 Mar;26(3):542-7.
Title: A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Author: Santoro, A|Gebbia, V|Pressiani, T|Testa, A|Personeni, N|Arrivas Bajardi, E|Foa, P|Buonadonna, A|Bencardino, K|Barone, C|Ferrari, D|Zaniboni, A|Tronconi, M C|Carteni, G|Milella, M|Comandone, A|Ferrari, S|Rimassa, L
PMID: 25538178
Journal: Oncotarget. 2017 Mar 7;8(10):17246-17257.
Title: Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Author: Luo, Xiangji|Jia, Weidong|Huang, Zhiyong|Li, Xiangcheng|Xing, Baocai|Jiang, Xiaoqing|Li, Jun|Si, Anfeng|Yang, Tian|Gao, Chunfang|Lau, Wan Yee|Shen, Feng
PMID: 27783997
Journal: Anticancer Res. 2017 Jul;37(7):3711-3715.
Title: Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases.
Author: Okano, Naohiro|Kasuga, Akiyoshi|Kawai, Kirio|Kobayashi, Takaaki|Naruge, Daisuke|Nagashima, Fumio|Furuse, Junji
PMID: 28668864
Journal: Pathol Oncol Res. 2018 Apr;24(2):237-244.
Title: Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.
Author: Rubovszky, Gabor|Budai, Barna|Ganofszky, Erna|Horvath, Zsolt|Juhos, Eva|Madaras, Balazs|Nagy, Tunde|Szabo, Eszter|Pinter, Tamas|Toth, Erika|Nagy, Peter|Lang, Istvan|Hitre, Erika
PMID: 28456898
Journal: Invest New Drugs. 2018 May 22. pii: 10.1007/s10637-018-0600-2.
Title: Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
Author: Finn, R S|Ahn, D H|Javle, M M|Tan, B R Jr|Weekes, C D|Bendell, J C|Patnaik, A|Khan, G N|Laheru, D|Chavira, R|Christy-Bittel, J|Barrett, E|Sawyer, M B|Bekaii-Saab, Tanios S
PMID: 29785570
Journal: J Cancer. 2018 Jul 16;9(16):2773-2777.
Title: The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study.
Author: Zhen, Liu|Jiali, Chen|Yong, Fang|Han, Xufeng|Hongming, Pan|Weidong, Han
PMID: 30123344
Journal: Eur Radiol. 2018 Sep 25. pii: 10.1007/s00330-018-5729-z.
Title: Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Author: Marquardt, Steffen|Kirstein, Martha M|Bruning, Roland|Zeile, Martin|Ferrucci, Pier Francesco|Prevoo, Warner|Radeleff, Boris|Trillaud, Herve|Tselikas, Lambros|Vicente, Emilio|Wiggermann, Philipp|Manns, Michael P|Vogel, Arndt|Wacker, Frank K
PMID: 30255257